IMEX   05356
INSTITUTO DE MEDICINA EXPERIMENTAL
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Assessment of new adjuvants formulations with the protein Transialidase to achieve immunoprotection against Trypanosoma cruzi infection
Autor/es:
BONTEMPI, IVÁN ALEJANDRO; VICCO, MIGUEL HERNÁN; CABRERA, GABRIEL; VILLAR, SILVINA; GONZÁLEZ, FLORENCIA; ROGGERO, EDUARDO; AMELOOT, PAUL; CALEWAERT, NICO; PÉREZ, ANA; MARCIPAR, IVÁN S.
Lugar:
Seattle
Reunión:
Congreso; KEYSTONE SYMPOSIA; 2014
Institución organizadora:
Fundación Bill and Melinda Gates
Resumen:
About the Disease? Chagas disease, caused by the protozoan parasite Trypanosoma cruzi (T. cruzi), represents a serious health problem in Latin America. About 8 million people are estimated to be infected, causing 11000 deaths per year. Although anti-parasitic treatments are available for recently infected individuals, in chronic patients drug efficiency is limited and may produce adverse reactions (occurring in up to 40% of treated patients). About the Vaccine? A new antigen-adjuvant combination was assessed to protect against Chagas disease. The single protein antigen in the formulation was a glycosylated mutant inactive trans-sialidase (mTS) and the adjuvant in the formulation was ISCOMATRIX (IMX). mTS has previously proven to be highly protective against T. cruzi infection using Freund Adjuvant. Herein, mTS expression and purification using Pichia pastoris has been optimized to obtain large amounts of quality protein. About the Adjuvant? Recombinant protein vaccines are safe but bring low immunological responses. The new generation of adjuvants is currently changing this weakness. ISCOMATRIX (IMX), is a saponin-based particulate adjuvant (which forms cage-like structures approximately 40 nm in diameter). In pre-clinical models, ISCOMATRIX vaccines have been demonstrated to generate broad humoral and cellular immune responses.